Conexeu executive acquires 750K shares at $0.001

The remaining 250,000 Performance Warrants will vest and become exercisable upon submission of a 510(k) application to the FDA.

Rhea-AI Filing Summary

Conexeu Sciences Inc. (CNXU) Chief Commercial Officer and director David Robert Bogart exercised 750,000 Performance Warrants on September 25, 2026, acquiring 750,000 common shares at $0.001 per share. His direct common-stock holdings after the transaction were 1,812,500 shares. His reported post-transaction balance was 250,000 Performance Warrants, which will vest and become exercisable upon the issuer submitting a 510(k) application to the U.S. Food and Drug Administration. Separately, 431,250 common shares were held by 0865546 B.C. Ltd., over which Bogart has sole voting and dispositive power.

Insider Trade Summary

750,000 shares exercised/converted

Exercise 3 txns

Insider Bogart David Robert

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise	Performance Warrants F1, F3	750,000	$0.00	$0.00
Exercise	Common Stock F1	750,000	$0.001	$750.00
holding	Common Stock F2	--	--	--

Holdings After Transaction: Performance Warrants — 250,000 contracts (Direct); Common Stock — 1,812,500 shares (Direct); Common Stock — 431,250 shares (Indirect, By 0865546 B.C. Ltd.)

Footnotes (3)

1. F1. The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.
2. F2. Held by 0865546 B.C. Ltd., over which the Reporting Person has sole voting and dispositive power.
3. F3. The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. 750,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.

Key Figures

Performance Warrants exercised: 750,000 warrants Exercise price: $0.001 per share Common shares acquired: 750,000 shares +3 more

6 metrics

Performance Warrants exercised 750,000 warrants September 25, 2026

Exercise price $0.001 per share Performance Warrants exercised September 25, 2026

Common shares acquired 750,000 shares September 25, 2026

Direct common shares following transaction 1,812,500 shares Reported after the September 25, 2026 transaction

Performance Warrants remaining 250,000 warrants Will vest and become exercisable upon the issuer submitting a 510(k) application to the U.S. Food and Drug Administration

Common shares held by 0865546 B.C. Ltd. 431,250 shares Indirect holding reported September 25, 2026

Key Terms

Performance Warrants, exercise price, vest, 510(k) application, +1 more

5 terms

Performance Warrants financial

"The Performance Warrants were granted on June 5, 2025"

exercise price financial

"have an exercise price of $0.001"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"The remaining 250,000 Performance Warrants will vest"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

510(k) application regulatory

"upon the Issuer submitting a 510(k) application"

A 510(k) application is a regulatory submission to the U.S. Food and Drug Administration showing that a new medical device is substantially similar to an already approved device, so it can be cleared for marketing without the longest, most rigorous approval process. For investors, a cleared 510(k) means faster, lower-cost market access and lower regulatory risk compared with full approvals, which can speed revenue and reduce uncertainty — like getting permission to sell a new model because it’s close to an existing one.

dispositive power regulatory

"has sole voting and dispositive power"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CNXU shares did David Robert Bogart acquire, and at what price?

Bogart acquired 750,000 common shares at $0.001 per share on September 25, 2026, by exercising 750,000 Performance Warrants.

Why were David Robert Bogart’s CNXU Performance Warrants granted, and when?

The Performance Warrants were granted on June 5, 2025 for services rendered to Conexeu Sciences.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/28/2026 - 05:41 PM Accepted by SEC EDGAR 09/28/2026 - 05:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bogart David Robert

(Last) (First) (Middle)

50 WEST LIBERTY STREET, SUITE 880

(Street)

RENO NEVADA 89501

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Conexeu Sciences Inc. [ CNXU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/25/2026		M(1)		750,000	A	$0.001	1,812,500	D
Common Stock								431,250	I	By 0865546 B.C. Ltd.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Warrants	$0.001	09/25/2026		M(1)			750,000	(3)	06/05/2030(3)	Common Stock	750,000	$0.00(3)	250,000	D

Explanation of Responses:

1. The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

2. Held by 0865546 B.C. Ltd., over which the Reporting Person has sole voting and dispositive power.

3. The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. 750,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.

	/s/ David Bogart	09/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)